Eldarov C, Gamisonia A, Chagovets V, et al
Safe and effective for overall wellness.
Key Points Available medical therapies for acromegaly are limited by moderate and variable efficacy, the need for life-long monthly intramuscular and/or deep subcutaneous depot, or thrice-daily subcutaneous injections, as well as adverse effects DG3173, an injectable somatostatin receptor ligand (SRL) in development, selectively suppresses secretion of growth hormone and seems to have negligible inhibitory effects on insulin secretion, which suggests it has a favourable hyperglycaemic adverse effect profile The investigational agent CAM2029 slowly releases octreotide from a liquid crystal matrix and is administered subcutaneously via thin, prefilled syringes, which facilitates ease of use and delivery Oral octreotide capsules (which are not yet approved) maintain biochemical control and improve symptoms in most patients who respond to injectable SRL therapy
It is particularly used in older patients to enhance immune function
The mucus plug, due to the infection, blocks the airways and prevents the passage of air, as it completely changes its consistency to a thicker and more viscous one that ends up adhering completely to the tissues
